Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VNRXBullishIndustry Newsnews

High materiality7/10

VolitionRx's Finger-Prick NETs Test Shows Strong Lab Correlation, Expands TAM

Aug 12, 2026, 8:19 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive validation of a point-of-care test with strong lab correlation may raise expectations for accelerated adoption and TAM expansion, potentially lifting VNRX sentiment and multiple expansion. History shows small-cap diagnostics demos can spark short-term moves if paired with clear commercialization signals.

AI summary

What happened, with direct paths to the underlying reporting

VolitionRx reported strong correlation between its lateral flow finger-prick NETs prototype and the automated Nu.Q NETs lab test in sepsis patients, signaling a shift toward decentralized, point-of-care testing. With a $3.8B NETosis TAM and ~166 million global sepsis cases, the initiative could broaden Volition's addressable market, particularly via NGO partnerships in low-infrastructure regions, potentially accelerating commercialization.

Lateral flow NETs test correlates with lab Nu.Q NETs (Spearman 0.85, Pearson 0.88).
Finger-prick bedside test enables rapid, high-risk patient identification.
Global sepsis market ~166 million cases; 31.5% mortality (2021).
TAM for NETosis testing cited at $3.8B; decentralized testing expands reach.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.